scholarly journals Remdesivir for Covid-19 pneumonia in patients with severe chronic kidney disease: Case series and review of the literature

2022 ◽  
Author(s):  
Ahmad Al Bishawi ◽  
Hamad Abdel Hadi ◽  
Eman Elmekaty ◽  
Musaed Al Samawi ◽  
Arun Nair ◽  
...  
Keyword(s):  
Severe Renal Impairment ◽  
Treatment Options ◽  
Case Series ◽  
Antiviral Agent ◽  
Review Of The Literature ◽  
Active Metabolites ◽  
Disease Case ◽  
Severe Chronic Kidney Disease ◽  
Patient Groups ◽  
To Receive

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.

scholarly journals Rare cases of head and neck’s neuroendocrine carcinomas disease: Case series of 4 patients and review of the literature

2020 ◽  
Vol 66 ◽  
pp. 270-276
Author(s):  
Anas Bouzbouz ◽  
Bushra Abdulhakeem ◽  
Rabii Laababsi ◽  
Sami Rouadi ◽  
Reda Abada ◽  
...  
Keyword(s):  
Case Series ◽  
Review Of The Literature ◽  
Disease Case ◽  
Neuroendocrine Carcinomas

scholarly journals High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature

2019 ◽  
Vol 12 (4) ◽  
pp. 189-193 ◽  
Author(s):  
Jonathan T. Kapke ◽  
Robert J. Schneidewend ◽  
Zeeshan A. Jawa ◽  
Chiang-Ching Huang ◽  
Jennifer M. Connelly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Series ◽  
Leptomeningeal Disease ◽  
High Dose ◽  
Review Of The Literature ◽  
Disease Case

scholarly journals Sclerosing Mesenteritis: Diverse clinical presentations and dissimilar treatment options. A case series and review of the literature

2011 ◽  
Vol 4 (1) ◽  
pp. 17 ◽  
Author(s):  
Konstantinos Vlachos ◽  
Fotis Archontovasilis ◽  
Evangelos Falidas ◽  
Stavros Mathioulakis ◽  
Stefanos Konstandoudakis ◽  
...  
Keyword(s):  
Treatment Options ◽  
Case Series ◽  
Sclerosing Mesenteritis ◽  
Review Of The Literature ◽  
Clinical Presentations

Identifying stakeholder opinion regarding access to “high-cost medicines”: A systematic review of the literature

Open Medicine ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. 513-527 ◽  
Author(s):  
Philip Wahlster ◽  
Shane Scahill ◽  
Sanjay Garg ◽  
Zaheer-Ud-Din Babar
Keyword(s):  
Systematic Review ◽  
Ethical Issues ◽  
Treatment Options ◽  
System Level ◽  
Research Articles ◽  
Original Research ◽  
Review Of The Literature ◽  
Moral Issues ◽  
The Public ◽  
Patient Groups

AbstractObjective: To identify the viewpoints and perceptions of different stakeholders regarding high cost medicines (HCMs). Methods: A systematic review of the literature was performed to identify original research articles. Using predefined categories, data related to the viewpoints of different stakeholders was systematically extracted and analyzed. Results: Thirty seven original research articles matched the criteria. The main stakeholders identified include physicians, patients, public and health funding authorities. The influence of media and other economic and ethical issues were also identified in the literature. A large number of stakeholders were concerned about lack of access to HCMs. Physicians have difficulty balancing the the rational use of expensive drugs while at the same time acting as “patients’ advocate”. Patients would like to know about all treatment options, even if they may not be able to afford them. The process and criteria for reimbursement should be transparent and access has to be equitable across patient groups. Conclusion: Access to HCMs could be improved through transparency and involvement of all stakeholders, especially patients and the public. Moral issues and the “rule of rescue” could influence decision-making process significantly. At system level, objectivity is important to ensure that the system is equitable and transparent.

Small Bowel Adenocarcinoma Complicating Crohn's Disease: Case Series and Review of the Literature

2007 ◽  
Vol 73 (11) ◽  
pp. 1181-1187 ◽  
Author(s):  
Lesly A. Dossett ◽  
Lisa M. White ◽  
Dereck C. Welch ◽  
Alan J. Herline ◽  
Roberta L. Muldoon ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
De Novo ◽  
Metastatic Cancer ◽  
Case Series ◽  
Small Bowel Adenocarcinoma ◽  
Review Of The Literature ◽  
Disease Case ◽  
History Of

Colonic adenocarcinoma frequently complicates inflammatory bowel disease of the colon, but small bowel adenocarcinoma (SBA) is a rare complication of Crohn's disease (CD). We present two patients with SBA in CD and review the literature with regards to CD-related SBA. A 45-year-old male with a 17-year history of ileal CD presented with obstructive symptoms but no radiographic evidence of a mass. After laparoscopic ileocolectomy and repair of incidental ileosigmoid fistula, pathology showed a T3N0 adenocarcinoma within the ileal CD. Two years after his resection he was without evidence of disease. A 59-year-old male with a 15-year history of CD presented with an acute exacerbation. Small bowel follow through demonstrated a long ileal stricture for which he underwent an ileocolic resection. Postoperative pathology confirmed a T3N1 CD-related SBA. He died from metastatic cancer 3 months later. Review of the literature identified 154 cases of SBA complicating CD with several distinguishing features from de novo SBA. Patients with SBA and CD are, as a group, younger and more likely to be male. SBA is rarely diagnosed preoperatively in these patients, and has a poor prognosis due to its advanced stage at diagnosis.

Atypical and early symptoms of sporadic Creutzfeldt – Jakob disease: case series and review of the literature

2020 ◽  
pp. 1-12
Author(s):  
Grammatiki Katsikaki ◽  
Ioannis E. Dagklis ◽  
Petros Angelopoulos ◽  
Dimitrios Ntantos ◽  
Angeliki Prevezianou ◽  
...  
Keyword(s):  
Case Series ◽  
Review Of The Literature ◽  
Early Symptoms ◽  
Disease Case ◽  
Jakob Disease

Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of the literature

2016 ◽  
Vol 48 (8) ◽  
pp. 893-898 ◽  
Author(s):  
Lídia Roque Ramos ◽  
Christopher J. DiMaio ◽  
David B. Sachar ◽  
Ashish Atreja ◽  
Jean-Frédéric Colombel ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Autoimmune Pancreatitis ◽  
Bowel Disease ◽  
Case Series ◽  
Review Of The Literature ◽  
Disease Case ◽  
Inflammatory Bowel

scholarly journals Management of penoscrotal extramammary Paget disease: case series and review of the literature

2013 ◽  
Vol 20 (4) ◽  
pp. 311 ◽  
Author(s):  
P. Moretto ◽  
V.J. Nair ◽  
S. El Hallani ◽  
S. Malone ◽  
E. Belanger ◽  
...  
Keyword(s):  
Case Series ◽  
Review Of The Literature ◽  
Paget Disease ◽  
Disease Case

scholarly journals Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 196
Author(s):  
Yukinori Ozaki ◽  
Sakiko Miura ◽  
Ryosuke Oki ◽  
Teppei Morikawa ◽  
Keita Uchino
Keyword(s):  
Who Classification ◽  
Case Reports ◽  
Treatment Options ◽  
Case Series ◽  
Breast Tumors ◽  
World Health ◽  
Neuroendocrine Neoplasms ◽  
Low Grade ◽  
Review Of The Literature ◽  
Retrospective Case

Breast tumors with neuroendocrine (NE) differentiation comprise an uncommon and heterogeneous group of tumors, including invasive breast cancer of no special type (IBC-NST) with NE features, neuroendocrine tumors (NETs), and neuroendocrine carcinoma (NEC). The most recent World Health Organization (WHO) classification in 2019 defined neuroendocrine neoplasms (NENs) of the breast (Br-NENs) as tumors in which >90% of cells show histological evidence of NE differentiation, including NETs (low-grade tumors) and NEC (high-grade). Due to the low prevalence of these tumors and successive changes in their diagnostic criteria over the years, only limited evidence of these tumors exists, derived mainly from case reports and retrospective case series. Breast tumors with NE differentiation are usually treated like the more commonly occurring IBC-NSTs. Immunohistochemistry (IHC) of breast tumors with NE differentiation usually shows a hormone receptor (HR)-positive and human epidermal growth factor type 2 (HER2)-negative profile, so that hormonal therapy with cyclin-dependent kinase (CDK)4/6 inhibitors or other targeted agents would be reasonable treatment options. Herein, we present a review of the literature on breast tumors with NE differentiation as defined in the latest WHO 2019 classification, and discuss the clinical management of these tumors.

Sign in / Sign up

Export Citation Format

Share Document